HPCSA-registeredSAHPRA-authorisedPOPIA-secure

Docto24
Sign inCHECK ELIGIBILITY
Attention-deficit/hyperactivity disorder — medical cannabis evaluation

Condition · ICD-11 6A05

Attention-deficit/hyperactivity disorder

Reviewed by Dr. Placeholder C (HPCSA MP0XXXXX · Psychiatry) · Last updated · Published

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition with persistent patterns of inattention, hyperactivity, or impulsivity. Standard care is psychiatric assessment followed by stimulant medication (methylphenidate, lisdexamfetamine, amphetamine salts) or non-stimulant alternatives (atomoxetine, guanfacine, clonidine), often combined with behavioural strategies and educational accommodations. Cannabinoid therapy for ADHD is among the **thinnest-evidence indications** evaluated under Section 21, and it is offered only after honest discussion of the evidence gap. It is never first-line, rarely second-line, and most appropriate as a last-line consideration in adults with refractory anxiety or sleep disturbance co-occurring with ADHD that has not responded to conventional combinations.

What the evidence says

Cooper et al (2017) ran a small pilot RCT of an oromucosal THC:CBD spray in adults with ADHD and found a non-significant trend toward symptom improvement. Mansell et al (2022) systematic review concluded that controlled-trial evidence for cannabinoids in ADHD is inadequate to support routine use; subjective patient reports of benefit exist but are largely confounded by co-occurring anxiety and sleep disturbance. International ADHD treatment guidelines do not endorse cannabinoids. The honest summary: there is no robust evidence that cannabinoids treat ADHD core symptoms. Where they may help selected adult patients is in associated anxiety, sleep disturbance, or stimulant-related side-effect burden — and even there, the case is weak and decided patient-by-patient.

How the doctor will evaluate you

For ADHD specifically, the doctor will require psychiatric correspondence confirming the diagnosis, a documented trial of standard stimulant or non-stimulant therapy with reasons for inadequate response or discontinuation, and an explicit identification of the symptom being targeted (typically anxiety, sleep disturbance, or stimulant side effects rather than core attention symptoms). The doctor will be conservative: cannabinoid adjunct in ADHD is offered to adults only, with no history of psychotic illness, no active substance-use disorder, and with continued psychiatric oversight. CBD-only or CBD-leaning regimens are the only appropriate starting point.

When to see a doctor urgently

  • Patient under 18 — cannabinoid therapy in paediatric ADHD is not appropriate outside specialist epilepsy contexts
  • History of psychotic illness or strong family history — THC contraindicated
  • Active substance-use disorder or recent cannabis-use disorder — cannabinoid therapy is unsafe
  • No psychiatric ADHD diagnosis on record — cannabinoid prescribing without confirmed diagnosis is inappropriate
  • Patient seeking cannabinoid as an alternative to stimulant therapy without trial of conventional options — not supported

If any of the above apply, seek in-person medical care — do not wait for a remote Section 21 consultation.

The South African Section 21 pathway

ADHD applications under the SA Section 21 pathway are uncommon and carry a higher evidence-bar at SAHPRA. Applications are stronger when targeted at a specific co-occurring symptom (anxiety, insomnia, stimulant-related anorexia) rather than at core ADHD symptoms. Psychiatric correspondence is generally expected. Authorisations are conservative and frequently reviewed.

Frequently asked

Can medical cannabis treat my ADHD?
Honestly, the evidence does not support cannabinoids as a treatment for the core attention or hyperactivity symptoms of ADHD. Where they may help selected adult patients is with co-occurring anxiety, sleep disturbance, or stimulant side effects. They are not a substitute for conventional ADHD treatment.
Will it interact with my stimulant medication?
Both THC and CBD affect CYP450 enzymes that metabolise some stimulants. The interaction is rarely clinically dangerous but can shift stimulant levels. The doctor will coordinate with your treating psychiatrist before any cannabinoid trial — solo prescribing without psychiatric oversight is not appropriate for ADHD.
Why is the bar so high for cannabinoids in ADHD?
Because the controlled-trial evidence is thin and there are real risks — particularly THC-related cognitive effects in a population that already has executive-function challenges. We are honest about this rather than offering false hope. For most patients with ADHD, optimising conventional therapy or addressing co-occurring conditions directly is a better path.
Is CBD-only safer than THC-containing for ADHD?
Yes — substantially. CBD-only regimens carry no cognitive-impairment or dependence risk and are the only appropriate starting point in any ADHD adjunctive use. THC is essentially never first-line in ADHD because the cognitive trade-offs almost always work against rather than for executive function. If a patient does not respond to CBD-only, escalating to THC is rarely the right next step.
What about microdosing? Is that an option?
Microdosing — typically very low-dose THC (≤2.5 mg) split through the day — is sometimes raised by patients but is not part of the standard Section 21 framework for ADHD. The evidence base is anecdotal, the dosing is hard to verify outside laboratory settings, and the framing risks normalising daily THC use without a clear clinical endpoint. The doctor will not endorse it as a primary strategy.

Related conditions

Glossary — terms used on this page

Quick definitions for terminology referenced above. Each links to a fuller entry.

Think this might apply to you? An HPCSA-registered doctor will review your case.

START ELIGIBILITY REVIEW

R500 consultation · R400 SAHPRA fee per product · 3–7 days end-to-end